Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Total Non-Current Liabilities (2024 - 2025)

Historic Total Non-Current Liabilities for Crinetics Pharmaceuticals (CRNX) over the last 5 years, with Q3 2025 value amounting to $121.0 million.

  • Crinetics Pharmaceuticals' Total Non-Current Liabilities rose 1644.64% to $121.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.0 million, marking a year-over-year increase of 1644.64%. This contributed to the annual value of $109.0 million for FY2024, which is 1320.66% up from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Total Non-Current Liabilities of $121.0 million as of Q3 2025, which was up 1644.64% from $115.7 million recorded in Q2 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' Total Non-Current Liabilities peaked at $121.0 million during Q3 2025, and registered a low of $96.2 million during Q4 2023.
  • Its 3-year average for Total Non-Current Liabilities is $108.0 million, with a median of $105.6 million in 2025.
  • The largest annual percentage gain for Crinetics Pharmaceuticals' Total Non-Current Liabilities in the last 5 years was 1644.64% (2025), contrasted with its biggest fall of 1065.7% (2025).
  • Quarter analysis of 3 years shows Crinetics Pharmaceuticals' Total Non-Current Liabilities stood at $96.2 million in 2023, then rose by 13.21% to $109.0 million in 2024, then increased by 11.02% to $121.0 million in 2025.
  • Its last three reported values are $121.0 million in Q3 2025, $115.7 million for Q2 2025, and $105.6 million during Q1 2025.